ACTON, Mass.--(BUSINESS WIRE)--Cognoptix announced today the strong results of a multi-site clinical trial of its SAPPHIRE II eye test designed to identify Alzheimer’s disease patients via a beta-amyloid (Ab) signature in their eyes. By detecting a specific fluorescent signature of ligand-marked Ab in the supranucleus region of the human lens, SAPPHIRE II achieved a sensitivity of 85% and a specificity of 95% in differentiating 20 patients who were clinically diagnosed with probable Alzheimer’s Disease (AD) from a group of 20 age-matched healthy volunteers. These results validate the previous proof-of-concept clinical trial of the Cognoptix drug/device combination eye test. In addition, the SAPPHIRE II test showed excellent correlation to PET amyloid brain imaging.
Help employers find you! Check out all the jobs and post your resume.
